Detailed explanation of the instructions for Bituvi/Bikernoprenol Tablets: from indications to medication precautions

Biktarvy is a compound antiretroviral drug mainly used to treat adults and children infected with HIV-1. It contains three active ingredients: Bictegravir (BIC), Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF). These ingredients work together through different mechanisms to effectively inhibit the replication of HIV virus, thereby helping patients control viral load, maintain immune system function, and delay the progression of AIDS.

1. Indications

Bituwei is suitable for the following two types of patients:

1. Initial treatmentHIV-1-infected adults and children weighing more than 14 kilograms: Bituvi, as a complete antiretroviral treatment regimen, can be used for the initial treatment of these patients. For patients who have never received antiretroviral therapy, Bituva provides comprehensive viral suppression through its three-in-one drug combination to help patients achieve sustained virological suppression.

2.Patients who have achieved virological suppression: For those adults and children who have received antiretroviral therapy and whose HIV-1 RNA level is less than 50 copies/ml, BITOVIR can be used as an alternative treatment. Such patients need to have no treatment failure and no resistance mutations to the three components of BIC (BIC, FTC, and TAF). This makes Bitavid an ideal alternative in stabilization treatment.

Through the synergistic effect of its three components, Bituvi not only effectively inhibits the replication of the HIV virus, but also reduces the risk of drug resistance and helps patients maintain good virological suppression during long-term treatment.

2. Usage and dosage

The dosage of BITOVIL varies based on the patient's weight and age. The recommended dose for adults and pediatric patients weighing more than 25 kg is one tablet daily, with specifications of bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg. This dose can meet the needs of conventional antiviral treatment and help patients achieve long-term and stable viral suppression.

For those weighing more thanFor pediatric patients weighing 14 kg but less than 25 kg, the recommended dose is one tablet per day, with specifications of bictegravir 30 mg, emtricitabine 120 mg and tenofovir alafenamide 15 mg. This dosage takes into account differences in children's weight, ensuring the treatment is safe and effective.

Pregnant women can also use Bitovil, taking one tablet daily (specifications are 50mg BIC, 200mg FTC and 25mg TAF), but there is currently insufficient long-term data to fully evaluate its safety during pregnancy. Nonetheless, use during pregnancy should be done with caution and under the guidance of a physician.

3. Patients with liver damage

Bitovil is not recommended for use in patients with severe hepatic impairment. Impaired liver function may affect drug metabolism and clearance, resulting in excessive drug concentration in the body, thereby increasing the risk of adverse reactions. For patients with impaired liver function, doctors may choose other drug regimens for treatment. For patients with mild and moderate liver damage, strict monitoring is required when using Bituvi to ensure the safety of drug treatment.

Four Notes

When using Bituvit, patients need to pay attention to drug resistance monitoring, liver function monitoring, renal function monitoring, drug interactions, allergic reactions and side effects, etc. Although the side effects of Bituvit are relatively mild, some patients may experience common side effects such as headache, nausea, fatigue, and insomnia. If severe allergic reactions or adverse reactions occur (such as rash, jaundice, abnormal liver function, etc.), you should stop using the drug immediately and seek medical help.

Reference materials:https://www.biktarvy.com/